Lifeward launches ReWalk 7 exoskeleton sales in the U.S.
Lifeward launched U.S. sales of the ReWalk 7 personal exoskeleton following FDA clearance.
Evidence notes
- The launch followed FDA clearance in March 2025.
- The product is used to support standing and walking for individuals with spinal cord injury.
Company context
Lifeward, formerly ReWalk Robotics, develops wearable robotic exoskeletons and rehabilitation technologies for people with mobility impairments.